# Haemanthus

A blood-testing startup whose patent was public for 109 days before the first news story. In the news since May 10, 2025.

Researched with Autumn (https://www.autumn.ai) from public records. Updated 2026-11-16. 13 sources. All stealth startups: https://www.autumn.ai/resources/stealth-startups

Haemanthus is an Austin startup that says it uses lasers to detect disease in blood, saliva and urine. Its first patent was public from January 21, 2025, 109 days before the first news stories. Its chief executive is Billy Evans, the partner of Theranos founder Elizabeth Holmes; the company says Holmes has no role in it.

Patent was public 109 days before the first press.

## Facts

- Legal name: Haemanthus, Inc.
- Sector: Medical diagnostics
- Based in: Austin, TX
- Website: https://www.haemanthus.com
- What the site says today: Haemanthus reads the complete molecular story of health. Detecting disease earlier. Saving lives.
- Signals: Patent, Incorporation filing, Subdomain certificate

## The paper trail

Certificate validity starts can precede CT logging; they do not always establish an exact first-public date.

- **Feb 2024** · Incorporation filing: Haemanthus, Inc. registered in Texas. Newsweek reported that records it reviewed show Haemanthus, Inc. registered in Texas in February 2024 as a foreign for-profit corporation. [1](https://www.newsweek.com/elizabeth-holmes-partner-rakes-millions-new-blood-test-machine-2070573)
- **Mar 1, 2024** · Patent: Patent priority date. Google Patents lists March 1, 2024 as the priority date of the company's first patent. [1](https://patents.google.com/patent/US12203862B1/en)
- **Jul 2, 2024** · Patent: Patent application filed. Application 18/762,412, "Raman spectroscopy system", was filed by Haemanthus Inc. The inventors are Joseph G. LaChapelle and Roger S. Cannon. [1](https://patents.google.com/patent/US12203862B1/en)
- **Sep 17, 2024** · Patent: Inventors assign the application to Haemanthus, Inc.. The assignment from LaChapelle and Cannon to the company is dated September 17, 2024. [1](https://patents.google.com/patent/US12203862B1/en)
- **Jan 14, 2025** · Patent: Fifth related application filed. Between July 16, 2024 and January 14, 2025 the same two inventors filed four more Raman spectroscopy applications assigned to Haemanthus. [1](https://patents.google.com/patent/US20250277699A1/en) [2](https://patents.google.com/patent/US12618714B2/en) [3](https://patents.google.com/patent/US20250277744A1/en) [4](https://patents.google.com/patent/US20250277745A1/en)
- **Jan 21, 2025** · Patent: US patent 12,203,862 granted and published. From this day the company's name, its inventors and a description of its laser system were public on the patent record. [1](https://patents.google.com/patent/US12203862B1/en)
- **May 10, 2025** · Press: The New York Times and NPR report on the company. The first news stories appeared 109 days after the patent was published and 312 days after it was filed. NPR's report cited the January patent. [1](https://www.nytimes.com/2025/05/10/business/elizabeth-holmes-partner-blood-testing-startup.html) [2](https://www.npr.org/2025/05/10/nx-s1-5393950/elizabeth-holmes-theranos-billy-evans-blood-testing)
- **May 11, 2025** · Public record: Company responds on X. NPR and Fortune quoted the company's account: "Elizabeth Holmes has zero involvement in Haemanthus," and "she has no role, now or future." It named Billy Evans as its CEO. [1](https://www.npr.org/2025/05/10/nx-s1-5393950/elizabeth-holmes-theranos-billy-evans-blood-testing) [2](https://fortune.com/2025/05/12/theranos-elizabeth-holmes-billy-evans-haemanthus-blood-testing-startup/)
- **May 22, 2025** · Subdomain certificate: Certificate issued for www.haemanthus.com. Certificate transparency logs show the first certificate for the www host twelve days after the first stories. The domain had been a parked for-sale page as late as 2022. [1](https://crt.sh/?q=haemanthus.com) [2](https://web.archive.org/web/20220308205137/http://haemanthus.com/)
- **Mar 16, 2026** · Founder departure: Chief technology officer says he resigned. Joseph LaChapelle, an inventor on the patent, told Forbes he resigned on March 16, 2026, as quoted by Fortune. [1](https://fortune.com/2026/10/25/elizabeth-holmes-partner-billy-evans-haemanthus-blood-testing-startup-theranos/)
- **May 5, 2026** · Patent: Second patent granted. US 12,618,714, "Raman spectroscopy system with standoff detection", was granted to Haemanthus with the same two inventors. [1](https://patents.google.com/patent/US12618714B2/en)

## The records themselves

- Patent, Jan 21, 2025: US 12,203,862 B1: bibliographic record. Look at the assignee line: it names Haemanthus Inc. The inventors are Joseph G. LaChapelle and Roger S. Cannon; granted January 21, 2025. [Full record at Google Patents](https://patents.google.com/patent/US12203862B1/en) (captured Nov 16, 2026, excerpt)
- Patent, Jan 21, 2025: US 12,203,862 B1: Figure 1. Figure 1 from Haemanthus’s granted patent: the Raman spectroscopy system drawing, rotated for reading. [Full record at USPTO](https://patentimages.storage.googleapis.com/80/3e/99/7a61d00040bb3e/US12203862.pdf#page=7) (captured Nov 16, 2026, excerpt)

## Subdomains

- www.haemanthus.com, certificate record May 22, 2025 [1](https://crt.sh/?q=haemanthus.com)
- mqtt.dev.haemanthus.com, certificate record Jul 4, 2025 [1](https://crt.sh/?q=haemanthus.com)
- supabase.dev.haemanthus.com, certificate record Aug 11, 2025 [1](https://crt.sh/?q=haemanthus.com)
- app.dev.haemanthus.com, certificate record Aug 13, 2025 [1](https://crt.sh/?q=haemanthus.com)

## Founders

- [Billy Evans](https://www.autumn.ai/resources/stealth-startups/people/billy-evans), Chief executive: Named chief executive in Haemanthus's own account in May 2025, as quoted by NPR; earlier at Luminar Technologies.

## What we don't know

- Whether the technology works. Fortune reported in October 2026 that the company had no product on sale and no published data.
- How much it has raised. Reported figures range from $3.5 million to as much as $20 million, and no SEC Form D was found.
- When the company was first formed. The Texas registration is as a foreign corporation, so it was formed elsewhere first.
- Who its investors are.

## Sources

1. https://www.newsweek.com/elizabeth-holmes-partner-rakes-millions-new-blood-test-machine-2070573
2. https://patents.google.com/patent/US12203862B1/en
3. https://patents.google.com/patent/US20250277699A1/en
4. https://patents.google.com/patent/US12618714B2/en
5. https://patents.google.com/patent/US20250277744A1/en
6. https://patents.google.com/patent/US20250277745A1/en
7. https://www.nytimes.com/2025/05/10/business/elizabeth-holmes-partner-blood-testing-startup.html
8. https://www.npr.org/2025/05/10/nx-s1-5393950/elizabeth-holmes-theranos-billy-evans-blood-testing
9. https://fortune.com/2025/05/12/theranos-elizabeth-holmes-billy-evans-haemanthus-blood-testing-startup/
10. https://crt.sh/?q=haemanthus.com
11. https://web.archive.org/web/20220308205137/http://haemanthus.com/
12. https://fortune.com/2026/10/25/elizabeth-holmes-partner-billy-evans-haemanthus-blood-testing-startup-theranos/
13. https://patentimages.storage.googleapis.com/80/3e/99/7a61d00040bb3e/US12203862.pdf#page=7

## The Autumn prompt

> Build a profile of five early companies, one row each: LuxSemi Inc. (luxsemi.com, assignee of US patent US12640820B1), Instant Expert (new company of Max Kolysh, who founded Dover), Granite Robotics, Inc. (graniterobotics.ai, Delaware, 2026), Fide AI, Inc. (fideai.org, Delaware, 2026) and Haemanthus (blood testing startup, assignee of US patent US12203862B1). For each, find the legal name, what it is building, sector, headquarters, website and what the site says today, founders, every dated public record (incorporation, domain registration, patents with priority, filing and grant dates, SEC Form D, job posts, launch posts), money raised, and the first press article about it with outlet and date.

Run your own: https://platform.autumn.ai/sign-up

Corrections and removal requests: founders@autumnai.com
